[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-intraepithelial-neoplasia-grade-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-intraepithelial-neoplasia-grade-2":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100649191","evaluation-of-low-thermal-argon-plasma-devitalization-for-the-treatment-of-cin-2-versus-standard-of-active-surveillance-100649191",false,"NCT07730645","Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance","Evaluation of Low-thermal Argon Plasma Devitalization (LtAPD) for the Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade 2 Versus Standard of Active Surveillance","CINPLASTA","Inclusion Criteria:\n\n* Female sex\n* Age 18 - 40 years at the time of signing the informed consent\n* Histologically confirmed CIN 2\n* Full visibility of the entire transformation zone (Type 1 or Type 2) and entire lesion in colposcopy\n* Ability to understand the nature of the clinical investigation and voluntarily signs the informed consent document prior to any study-related procedures\n\nExclusion Criteria:\n\n* Histologically confirmed CIN other than CIN 2, or indication of (micro-) invasive cervical disease\n* CIN lesions extending to the vaginal vault or suspicion of endocervical disease\n* Current pregnancy or planned pregnancy within the next 6 months\n* Presence of severe local inflammation or active infection\n* Presence of a severe cardiovascular, neurological, psychiatric, endocrine, or hematological disease, immunocompromised condition or malignant tumor of any origin, as judged by the investigator\n* Participation in an interfering clinical study, as judged by the investigator","FEMALE","18 Years","40 Years",{"count":21,"type":22},264,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment (\"active surveillance\"), in achieving complete healing of a tissue abnormality on the cervix called CIN 2, after 6 months. This will be confirmed by examining tissue samples under a microscope (histopathological examination).",[28,29,30],"Cervical Intraepithelial Neoplasia Grade 2 (CIN2)","Cervical Intraepithelial Neoplasia Grade 2","CIN2",[30,29,32,33,34,35,36,37],"Low-thermal argon plasma devitalization","LtAPD","Plasma application","Plasma treatment","Physical plasma","Physical plasma treatment","NOT_YET_RECRUITING","2026-07-31",{"date":41,"type":42},"2026-08-03","ACTUAL",{"date":44,"type":22},"2026-08-17",{"date":46,"type":22},"2029-09-30",{"name":48,"class":49},"University Hospital Tuebingen","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100547103","evaluation-of-the-precursor-m-in-cin2-100547103","NCT06403618","Evaluation of the PreCursor-M+® in CIN2","Evaluation of the PreCursor-M+® Assay Performance in the Management of Women Diagnosed With CIN2","Inclusion Criteria:\n\n1. age at diagnosis of 18 years or older;\n2. histological confirmation of CIN2 after colposcopic-guided cervical biopsy or conservative surgical treatment, including loop electrosurgical excision procedure (LEEP) and laser conization;\n3. known HPV test result at baseline;\n4. ability to understand and sign the informed consent;\n5. written informed consent given.\n\nExclusion criteria:\n\n1. unknown HPV test result at diagnosis;\n2. vulnerable patients.",{"count":59,"type":22},100,"OBSERVATIONAL","The goal of this observational study is to to evaluate the accuracy and sensitivity of PreCursor-M+ on a post-aliquot of liquid-based cytology (LBC) cervical samples (biopsy) obtained by physicians in a group of women with histologically-proven diagnoses of CIN2.\n\nThe PreCursor-M+® assay is a multiplex real-time methylation specific PCR test that identifies the level of promotor methylation of the host cell genes FAM19A4 and miR124-2, known biomarkers associated with cervical carcinoma and transforming CIN in cervical cells.\n\nTo evaluate the clinical course of CIN2 at 2 years after the first diagnosis, with an interval evaluation at 6 months.\n\nAfter enrolment, women will be divided into two groups: \"active surveillance\" and \"immediate treatment\". In the first group, clinical outcomes to be assessed, in relation to the PreCursor-M+ result at baseline, will include regression to \\\u003CCIN2, persistence of CIN2, and progression to CIN3+. In the second group, we will evaluate the histological diagnosis at cone specimen (downgrading or upgrading) and the 2-year cumulative incidence of CIN2+ recurrence based on the PreCursor-M+ result at baseline.",[29],"RECRUITING","2025-05-20",{"date":66,"type":42},"2025-05-23",{"date":68,"type":42},"2024-06-17",{"date":70,"type":22},"2027-06-17",{"name":72,"class":49},"European Institute of Oncology"]